Literature DB >> 22580489

Altitude illness: update on prevention and treatment.

Richard P Eide1, Chad A Asplund.   

Abstract

Altitude illness is a broad category of disease encompassing acute mountain sickness (AMS), high-altitude cerebral edema (HACE), and high-altitude pulmonary edema (HAPE) that can affect persons who travel to altitude without adequate acclimatization. Initial symptoms of AMS and the more serious HACE or HAPE can be subtle, and it is important that the practitioner be able to recognize and differentiate between these diagnoses because they can progress rapidly and be fatal if untreated. There are well-established criteria and many proven therapies both for prophylaxis and treatment of altitude illness; however, despite intense research efforts, the specific mechanisms of these complex diseases remain elusive. Adequate acclimatization via controlled ascent remains the most important factor in preventing altitude illness, although prophylactic pharmacotherapy also may be useful. Rapid descent remains the most important treatment factor, although treatment at altitude with various therapies is possible for mild cases with adequate resources.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22580489     DOI: 10.1249/JSR.0b013e3182563e7a

Source DB:  PubMed          Journal:  Curr Sports Med Rep        ISSN: 1537-890X            Impact factor:   1.733


  9 in total

1.  Differential modulation of S1PR(1-5) and specific activities of SphK and nSMase in pulmonary and cerebral tissues of rats exposed to hypobaric hypoxia.

Authors:  Sonam Chawla; Shweta Saxena
Journal:  Lipids       Date:  2014-11-16       Impact factor: 1.880

Review 2.  Managing collapsed or seriously ill participants of ultra-endurance events in remote environments.

Authors:  Martin D Hoffman; Ian R Rogers; Jeremy Joslin; Chad A Asplund; William O Roberts; Benjamin D Levine
Journal:  Sports Med       Date:  2015-02       Impact factor: 11.136

3.  Nrf2 activation: a potential strategy for the prevention of acute mountain sickness.

Authors:  Christina Lisk; Joe McCord; Swapan Bose; Tim Sullivan; Zoe Loomis; Eva Nozik-Grayck; Thies Schroeder; Karyn Hamilton; David C Irwin
Journal:  Free Radic Biol Med       Date:  2013-05-27       Impact factor: 7.376

Review 4.  Interventions for treating acute high altitude illness.

Authors:  Daniel Simancas-Racines; Ingrid Arevalo-Rodriguez; Dimelza Osorio; Juan Va Franco; Yihan Xu; Ricardo Hidalgo
Journal:  Cochrane Database Syst Rev       Date:  2018-06-30

Review 5.  Efficacy of NSAIDs for the prevention of acute mountain sickness: a systematic review and meta-analysis.

Authors:  Anil Pandit; Paras Karmacharya; Ranjan Pathak; Smith Giri; Madan R Aryal
Journal:  J Community Hosp Intern Med Perspect       Date:  2014-09-29

6.  Acute shortness of breath in an adult.

Authors:  Haley Ringwood; Morteza Khodaee; Darcy K Selenke
Journal:  Asian J Sports Med       Date:  2014-11-10

Review 7.  Systematic Review of the Effects of Phosphodiesterase-5 Inhibitors and Dexamethasone on High Altitude Pulmonary Edema (HAPE).

Authors:  Amy Bliss; Sonia Mahajan; Kevin M Boehm
Journal:  Spartan Med Res J       Date:  2019-03-04

8.  Regulation of CYP450 and drug transporter mediated by gut microbiota under high-altitude hypoxia.

Authors:  Xue Bai; Jianxin Yang; Guiqin Liu; Junbo Zhu; Qian Wang; Wenqi Gu; Linli La; Xiangyang Li
Journal:  Front Pharmacol       Date:  2022-09-15       Impact factor: 5.988

9.  Expression of Aquaporin-1 and Aquaporin-5 in a Rat Model of High-Altitude Pulmonary Edema and the Effect of Hyperbaric Oxygen Exposure.

Authors:  Jiewen Tan; Chunjin Gao; Cong Wang; Linlin Ma; Xiaomin Hou; Xuehua Liu; Zhuo Li
Journal:  Dose Response       Date:  2020-10-30       Impact factor: 2.658

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.